Geode Capital Management
CDTX

Geode Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Geode Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-520,591
Closed -$115M – 4531
2025
Q4 		$115M Buy
520,591
+116,477
+29% +$18.8M 0.01% 980
2025
Q3 		$38.7M Buy
404,114
+32,104
+9% +$2.05M ﹤0.01% 1643
2025
Q2 		$18.1M Buy
372,010
+317,027
+577% +$7.62M ﹤0.01% 2007
2025
Q1 		$1.18M Buy
54,983
+1,915
+4% +$42.5K ﹤0.01% 3249
2024
Q4 		$1.43M Buy
53,068
+170
+0.3% +$2.76K ﹤0.01% 3243
2024
Q3 		$569K Buy
52,898
+9,771
+23% +$117K ﹤0.01% 3548
2024
Q2 		$515K Buy
43,127
+1,213
+3% +$16.6K ﹤0.01% 3558
2024
Q1 		$771K Buy
41,914
+1,620
+4% +$23.3K ﹤0.01% 3458
2023
Q4 		$640K Hold
40,294
– – ﹤0.01% 3523
2023
Q3 		$759K Buy
40,294
+3,908
+11% +$76.7K ﹤0.01% 3438
2023
Q2 		$822K Buy
36,386
+3,403
+10% +$80K ﹤0.01% 3433
2023
Q1 		$838K Buy
32,983
+3,347
+11% +$95K ﹤0.01% 3424
2022
Q4 		$448K Buy
29,636
+387
+1% +$4.62K ﹤0.01% 3705
2022
Q3 		$367K Buy
29,249
+4,147
+17% +$57.2K ﹤0.01% 3893
2022
Q2 		$245K Buy
25,102
+1,298
+5% +$16K ﹤0.01% 4141
2022
Q1 		$396K Buy
23,804
+4,723
+25% +$80.1K ﹤0.01% 4060
2021
Q4 		$484K Hold
19,081
– – ﹤0.01% 4064
2021
Q3 		$854K Buy
19,081
+873
+5% +$33.2K ﹤0.01% 3763
2021
Q2 		$735K Sell
18,208
-11,310
-38% -$479K ﹤0.01% 3747
2021
Q1 		$1.57M Buy
29,518
+6,731
+30% +$332K ﹤0.01% 3371
2020
Q4 		$911K Buy
22,787
+383
+2% +$19K ﹤0.01% 3392
2020
Q3 		$1.28M Buy
22,404
+466
+2% +$32.9K ﹤0.01% 3113
2020
Q2 		$1.62M Buy
21,938
+10,938
+99% +$709K ﹤0.01% 2956
2020
Q1 		$545K Buy
11,000
+5,113
+87% +$306K ﹤0.01% 3250
2019
Q4 		$452K Buy
5,887
+87
+2% +$3.98K ﹤0.01% 3530
2019
Q3 		$231K Buy
5,800
+2,451
+73% +$82.4K ﹤0.01% 3716
2019
Q2 		$112K Buy
3,349
+235
+8% +$9.76K ﹤0.01% 3935
2019
Q1 		$165K Hold
3,114
– – ﹤0.01% 3782
2018
Q4 		$146K Hold
3,114
– – ﹤0.01% 3765
2018
Q3 		$274K Hold
3,114
– – ﹤0.01% 3657
2018
Q2 		$323K Buy
3,114
+929
+43% +$87.7K ﹤0.01% 3570
2018
Q1 		$174K Hold
2,185
– – ﹤0.01% 3730
2017
Q4 		$297K Sell
2,185
-215
-9% -$32.6K ﹤0.01% 3539
2017
Q3 		$388K Hold
2,400
– – ﹤0.01% 3445
2017
Q2 		$359K Sell
2,400
-1,077
-31% -$149K ﹤0.01% 3482
2017
Q1 		$542K Buy
3,477
+6
+0.2% +$1.05K ﹤0.01% 3279
2016
Q4 		$721K Buy
3,471
+1,565
+82% +$325K ﹤0.01% 3138
2016
Q3 		$436K Buy
1,906
+94
+5% +$21.7K ﹤0.01% 3304
2016
Q2 		$373K Buy
1,812
+461
+34% +$112K ﹤0.01% 3340
2016
Q1 		$343K Buy
1,351
+29
+2% +$6.68K ﹤0.01% 3412
2015
Q4 		$453K Buy
1,322
+238
+22% +$71.5K ﹤0.01% 3319
2015
Q3 		$275K Buy
+1,084
New +$310K ﹤0.01% 3527

Geode Capital Management's CDTX Position: Q1 2026 in Review

Geode Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 520,591 shares — an estimated $115M sold.

Geode Capital Management first reported a position in CDTX in Q3 2015 and held it in 42 quarters. The position peaked at $115M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • Geode Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Geode Capital Management sold 520,591 Cidara Therapeutics shares in Q1 2026, an estimated $115M.
  • Geode Capital Management first reported a position in Cidara Therapeutics in Q3 2015 and held it in 42 quarters.
  • Geode Capital Management's Cidara Therapeutics position peaked at $115M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.